Topical Lingual PYY & GLP1
Obesity / Cardiometabolic Disorders
Research/Pre-clinicalActive
Key Facts
Indication
Obesity / Cardiometabolic Disorders
Phase
Research/Pre-clinical
Status
Active
Company
About Gila Therapeutics
Gila Therapeutics is a San Diego-based biotech founded in 2018, targeting the massive obesity and cardiometabolic market with a first-of-its-kind neural signaling platform. The company's core technology involves topical lingual administration of peptides (e.g., PYY, GLP-1) to activate the brain's metabolic control centers via oral receptors, aiming to bypass systemic side effects like nausea. Having completed a successful Phase I trial with no treatment-related adverse events, Gila is advancing its pipeline through strategic partnerships and is positioned as a potential disruptor in the incretin therapy space by offering a non-systemic, convenient treatment modality.
View full company profileTherapeutic Areas
Other Obesity / Cardiometabolic Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Topical Lingual PYY | Gila Therapeutics | Phase 1 |